Ranibizumab: all 350 studies that test it

Page 1 of 4. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.Not yet recruitingNCT07864480Phase 4
• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDRecruitingNCT06847542Phase 3
• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling by invitationNCT05210803Phase 2
• Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During OperationRecruitingNCT05138029Phase 3
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)RecruitingNCT04853251Phase 4
• Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®RecruitingNCT04667039Phase 3
• A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVOCompletedNCT06176963Phase 2Results posted
• A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator ArmCompletedNCT04503551Phase 3Results posted
• Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
• Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMDCompletedNCT03805100Phase 3Results posted
• ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)CompletedNCT03362190Phase 2Results posted
• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedNCT03211234Phase 2Results posted
• Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg LucentisCompletedNCT03097068Phase 4Results posted
• A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist RanibizumabCompletedNCT02859441Phase 1/2Results posted
• Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic RetinopathyCompletedNCT02834663Phase 4Results posted
• A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)CompletedNCT02698566Phase 3Results posted
• Influence of Diabetes Control on Treatment of Diabetic Macular Edema With RanibizumabTerminatedNCT02665689Phase 4Results posted
• Rainbow Extension StudyCompletedNCT02640664Phase 3Results posted
• Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy TrialCompletedNCT02623426Phase 3Results posted
• Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02611778Phase 3Results posted
• Head to Head Study of Anti-VEGF Treatment.CompletedNCT02577107Phase 4Results posted
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular DegenerationCompletedNCT02510794Phase 2Results posted
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT02484690Phase 2Results posted
• The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid ExudatesCompletedNCT02448446Phase 1/2Results posted
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
• RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of PrematurityCompletedNCT02375971Phase 3Results posted
• Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula EdemaCompletedNCT02366468Phase 4Results posted
• Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DMECompletedNCT02363621Phase 2Results posted
• Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT02358889Phase 2Results posted
• A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) PatientsCompletedNCT02259088Phase 3Results posted
• Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMDCompletedNCT02161575Phase 4Results posted
• A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD PatientsCompletedNCT02130024Phase 4Results posted
• Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFCompletedNCT02118831Phase 1/2Results posted
• Performance Assessment Tests in Working Individuals With DME Following Treatment With RanibizumabCompletedNCT02107131Phase 4Results posted
• A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.CompletedNCT02034006Phase 3Results posted
• Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment PhaseTerminatedNCT02032173Phase 3Results posted
• Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected EyeCompletedNCT01986907Phase 4Results posted
• Safety and Efficacy of Ranibizumab for Diabetic Macular EdemaCompletedNCT01982435Phase 1/2Results posted
• Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT01976338Phase 3Results posted
• Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT01976312Phase 3Results posted
• Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)CompletedNCT01972789Phase 4Results posted
• Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMDCompletedNCT01958918Phase 4Results posted
• Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDCompletedNCT01948830Phase 3Results posted
• Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular DegenerationCompletedNCT01926977Phase 1/2Results posted
• Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT01922102Phase 3Results posted
• Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration StudyCompletedNCT01914159Phase 2Results posted
• An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 3Results posted
• Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)CompletedNCT01884597Phase 1/2Results posted
• To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular EdemaCompletedNCT01846299Phase 3Results posted
• Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.CompletedNCT01840410Phase 3Results posted
• Indocyanine Angiographic Changes of Choroidal Neovascularization by RanibizumabCompletedNCT01810042Phase 4Results posted
• Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular DegenerationCompletedNCT01780935Phase 3Results posted
• Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)CompletedNCT01775124Phase 4Results posted
• Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg RanibizumabCompletedNCT01748292Phase 3Results posted
• Bloodstream Absorption of Avastin and Lucentis After Injection Into the EyeCompletedNCT01661946Phase 3Results posted
• Ranibizumab and Bevacizumab for Diabetic Macular EdemaCompletedNCT01610557Phase 2Results posted
• Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein OcclusionCompletedNCT01599650Phase 3Results posted
• Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)CompletedNCT01594281Phase 2Results posted
• Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
• Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionCompletedNCT01535261Phase 3Results posted
• Dosing Study of Ranibizumab for Diabetic Retinal and Macular EdemaCompletedNCT01476449Phase 2Results posted
• Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving BevacizumabCompletedNCT01471691Phase 1/2Results posted
• Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal VasculopathyCompletedNCT01469156Phase 1/2Results posted
• Study EvAluating Genotypes While Using Lucentis 2CompletedNCT01464723Phase 4Results posted
• An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)CompletedNCT01442064Not applicableResults posted
• Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein OcclusionCompletedNCT01427751Phase 4Results posted
• Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMDCompletedNCT01414153Phase 2Results posted
• Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With RanibizumabTerminatedNCT01402544Phase 2/3Results posted
• Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT01396083Phase 3Results posted
• Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT01396057Phase 3Results posted
• Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous ChorioretinopathyCompletedNCT01325181Phase 1/2Results posted
• Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to BevacizumabCompletedNCT01292798Phase 1/2Results posted
• A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein OcclusionCompletedNCT01277302Phase 4Results posted
• Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)CompletedNCT01251978Phase 2Results posted
• Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)TerminatedNCT01225146Phase 1Results posted
• High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal TelangiectasiaCompletedNCT01205035Phase 2Results posted
• Extended Follow-up of Patients With Macular Edema Due to Retinal Vein OcclusionCompletedNCT01198327Phase 3Results posted
• Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusCompletedNCT01171976Phase 3Results posted
• Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)CompletedNCT01148511Phase 4Results posted
• Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)CompletedNCT01135914Phase 3Results posted
• Safety and Efficacy of Ranibizumab in Diabetic Macular EdemaTerminatedNCT01131585Phase 3Results posted
• A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)CompletedNCT01115556Phase 1/2Results posted
• A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationCompletedNCT01089517Phase 2Results posted
• Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 StudyCompletedNCT01077401Phase 2Results posted
• Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract SurgeryCompletedNCT01069341Phase 1Results posted
• A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)TerminatedNCT01025232Phase 1/2Results posted
• Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein OcclusionsCompletedNCT01003106Phase 1/2Results posted
• Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)CompletedNCT00996437Phase 2/3Results posted
• Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT00989989Phase 3Results posted
• Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT00901186Phase 2Results posted
• Lucentis in Advanced Macular DegenerationCompletedNCT00896779Phase 2Results posted
• A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)CompletedNCT00891735Phase 3Results posted
• Ranibizumab (Lucentis) for Polypoidal Choroidal VasculopathyCompletedNCT00837330Phase 1/2Results posted
• Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular EdemaCompletedNCT00826618Phase 1Results posted
• Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)CompletedNCT00775411Phase 2Results posted
• A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension StudyCompletedNCT00687804Phase 3Results posted
• Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)CompletedNCT00681889Phase 1Results posted
• Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal MelanomaCompletedNCT00680225Phase 3Results posted
• Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT00674323Phase 4Results posted
• Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)TerminatedNCT00668785Phase 2Results posted

← Ranibizumab overview